{
    "nctId": "NCT05802225",
    "briefTitle": "Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta\u00ae as Neoadjuvant Therapy of HER2-Positive Breast Cancer",
    "officialTitle": "A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta\u00ae as Neoadjuvant Therapy of HER2-Positive Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 374,
    "primaryOutcomeMeasure": "To compare the efficacy of BCD-178 and Perjeta as neoadjuvant therapy by studying the total pathological complete response (tpCR) rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent ;\n* Histologically confirmed diagnosis of invasive breast cancer;\n* Disease stage cT2-cT4, cN0-cN3, cM0;\n* Positive HER2 expression, negative estrogen and progesterone receptor expression;\n* ECOG score 0-1;\n* Adequate organ function;\n* Baseline LVEF \u2265 55%, as measured with the standard procedure;\n* Consent of women of childbearing potential to use highly effective methods of contraception, starting from the signing of the informed consent form, throughout the study and for 6 months after receiving the last dose of the product.\n\nExclusion Criteria:\n\n* Stage IV (metastatic) breast cancer;\n* A history of any systemic therapy for breast cancer;\n* Concomitant diseases and/or conditions that significantly increase the risk of adverse events during the study;\n* Pregnancy or breastfeeding, as well as pregnancy planning throughout the study and for 6 months after receiving the last dose of the product;\n* Hypersensitivity or allergy to any of the components of BCD-178, Perjeta, trastuzumab, carboplatin, and docetaxel.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}